Stockscreener 앱 받기
0.4301
28.60%
-0.1723
Aspire Biopharma Holdings Inc 주식(ASBP)의 최신 뉴스
ASBP Stock Price and Chart — NASDAQ:ASBP - TradingView
Aspire Biopharma provides development update on BUZZ BOMB supplement - Yahoo Finance
Aspire Biopharma (ASPH) Stock Explodes Over 160%: What's Behind the Monumental Surge? - Daily Chhattisgarh News
Pharma Stock Massively Bid Up Following New Product Announcement - The Globe and Mail
Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025 - ACCESS Newswire
Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - New Castle News
ASBP stock touches 52-week low at $0.22 amid sharp annual decline - Investing.com India
Sidoti Events, LLC's Virtual May Micro-Cap Conference - FinancialContent
Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Aspire Biopharma announces resale of up to 11.26M shares - MSN
Aspire Biopharma Holdings, Inc. SEC 10-Q Report - TradingView
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21 - ACCESS Newswire
Aspire Biopharma Holdings Inc (ASBP) Stock: A Comprehensive 52-Week Review - investchronicle.com
Was anything negative for Aspire Biopharma Holdings Inc (ASBP) stock last session? - uspostnews.com
Post-Trade Analysis: Aspire Biopharma Holdings Inc (ASBP) Slides -15.33, Closing at 0.36 - DWinneX
Aspire Biopharma Settles with Lenders, Extends Loan Maturities By Investing.com - Investing.com Nigeria
Aspire Biopharma Settles with Lenders, Extends Loan Maturities - Investing.com Australia
Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - The Joplin Globe
Press Release Distribution & PR Platform - ACCESS Newswire
Former Nasdaq Private Market President Takes LogicMark's Helm: Inside the AI-Driven Healthcare Tech Transformation - Stock Titan
Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17 - ACCESS Newswire
ASBPAspire Biopharma Holdings Inc Latest Stock News & Market Updates - Stock Titan
Aspire Biopharma starts production of pre-workout supplement By Investing.com - Investing.com South Africa
Aspire Biopharma starts production of pre-workout supplement - Investing.com Australia
Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement - standard-journal.com
Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - Weatherford Democrat
Aspire Biopharma Holdings Inc. (ASBP) reports earnings - Quartz
Aspire Biopharma Holdings, Inc. SEC 10-K Report - TradingView
ASBP stock touches 52-week low at $0.51 amid sharp annual decline - Investing.com Canada
ASBP stock touches 52-week low at $0.51 amid sharp annual decline By Investing.com - Investing.com South Africa
There is no way Aspire Biopharma Holdings Inc (ASBP) can keep these numbers up - SETE News
Sector Update: Health Care - MarketScreener
Aspire Biopharma Says Glatt Air Produces First Batch of Oral Mucosal Form of Aspirin -March 20, 2025 at 10:11 am EDT - Marketscreener.com
Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin - standard-journal.com
1.89%
3.74%
자본화:
|
볼륨(24시간):